13F Pro Quality Score

28.0/100

Rank #2,569 of 2,960 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

MDWD Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for MediWound Ltd. (MDWD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MDWD at 28.0/100 on a 32-signal composite quality model, placing it at rank #2,569 of 2,960 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), MediWound Ltd. reports quarterly revenue of $17.0M, net income of $-23.9M. Top institutional holders of MDWD by reported 13-F value include INVESTOR AB, Yelin Lapidot Management Ltd., Rosalind Advisors, based on the most recent SEC filings. MDWD trades on the Nasdaq exchange and files with the SEC under CIK 1593984. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDWD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MediWound Ltd. directly from SEC EDGAR.

Revenue

FY 2025

$17.0M

Net Income

FY 2025

$-23.9M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-16.1% YoY
$17.0MFY 2025
FY22 $26.5MFY23 $18.7MFY24 $20.2MFY25 $17.0M

Total Assets

+17.4% YoY
$86.3MFY 2025
FY22 $50.0MFY23 $66.5MFY24 $73.5MFY25 $86.3M

Get alerted when MDWD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MediWound Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put MDWD on your watchlist

Track score changes the day MediWound Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is MDWD a good stock to buy?

13F Pro's AI-powered analysis of MediWound Ltd. (MDWD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDWD are available on the MDWD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MDWD is classified as a small company.

Which hedge funds own MDWD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDWD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MediWound Ltd.'s investment landscape.